A correlation between tumor aggressiveness and CB2 receptor expression in breast cancer has been previously reported: tumors lacking estrogen or progesterone receptors, which are associated to low response rates to adjuvant therapies, express higher CB2 levels than steroid receptor-positive lesions [17]. The gene discussed is CNR2; the disease is breast carcinoma.